Share：
Share this content in WeChat
X
[Chinese][PDF]84275
• Review •
The application of 19F-MR molecular imaging in targeted drug delivery
YANG Jie  LI Yingbo  WU Li’na  WANG Kai  YANG Lili  SUN Xilin 

Cite this article as: Yang J, Li YB, Wu LN, et al. The application of 19F-MR molecular imaging in targeted drug delivery. Chin J Magn Reson Imaging, 2020, 11(10): 954-956, 960. DOI:10.12015/issn.1674-8034.2020.10.031.


[Abstract] In recent years, 19F magnetic resonance (19F-MR) molecular imaging represents a compelling option for studying targeted drug delivery. Due to the lack of endogenous fluorine in living organisms and the excellent sensitivity of 19F, nanomaterials including liquid perfluorocarbon (PFC) have been developed as ideal molecular imaging probes for 19F-MR imaging. The combination of 19F-MR imaging and targeted drug delivery presents an ideal modality for tumor-targeted theranostic, which improves the chances of diagnosis, therapy, efficacy monitoring and prognosis evaluation. In this review, we present our perspective on 19F-MR molecular imaging developments for the investigation of targeted drug delivery and stimuli-responsive drug release. And their application and the advantages and disadvantages are discussed, in order to provide theoretical basis and data support for the design, preparation, development and application of new multifunctional nanomaterials that can be used for 19F-MR molecular imaging.
[Keywords] 19F-MR molecular imaging；targeted drug delivery；perfluorocarbon；theranostic；stimuli-responsive drug release

YANG Jie TOF-PET/CT/MR Center, Fourth Hospital of Harbin Medical University, Harbin 150028, China; Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin 150028, China

LI Yingbo TOF-PET/CT/MR Center, Fourth Hospital of Harbin Medical University, Harbin 150028, China; Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin 150028, China

WU Li’na TOF-PET/CT/MR Center, Fourth Hospital of Harbin Medical University, Harbin 150028, China; Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin 150028, China

WANG Kai TOF-PET/CT/MR Center, Fourth Hospital of Harbin Medical University, Harbin 150028, China; Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin 150028, China

YANG Lili TOF-PET/CT/MR Center, Fourth Hospital of Harbin Medical University, Harbin 150028, China; Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin 150028, China

SUN Xilin* TOF-PET/CT/MR Center, Fourth Hospital of Harbin Medical University, Harbin 150028, China; Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin 150028, China

*Correspondence to: Sun XL, E-mail: sunxl@ems.hrbmu.edu.cn

Conflicts of interest   None.

ACKNOWLEDGMENTS  This work was part of National Natural Science Foundation of China No. 81627901 National Basic Research Program of China No. 2015CB931800 Heilongjiang Province Key Laboratory Fund of Molecular Imaging
Received  2020-04-30
Accepted  2020-06-18
DOI: 10.12015/issn.1674-8034.2020.10.031
Cite this article as: Yang J, Li YB, Wu LN, et al. The application of 19F-MR molecular imaging in targeted drug delivery. Chin J Magn Reson Imaging, 2020, 11(10): 954-956, 960. DOI:10.12015/issn.1674-8034.2020.10.031.

[1]
Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA: A Cancer J Clin, 2017, 67(2): 93-99.
[2]
Hill LK, Frezzo JA, Katyal P, et al. Protein-engineered nanoscale micelles for dynamic 19F magnetic resonance and therapeutic drug delivery. ACS Nano, 2019, 13(3): 2969-2985.
[3]
Xie D, Yu M, Kadakia RT, et al. 19F magnetic resonance activity-based sensing using paramagnetic metals. Accounts Chemical Res, 2020, 53(1): 2-10.
[4]
Hequet E, Henoumont C, Muller RN, et al. Fluorinated MRI contrast agents and their versatile applications in the biomedical field. Future Med Chemistry, 2019, 11(10): 1157-1175.
[5]
Suk JS, Xu QG, Kim N, et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Advanced Drug Delivery Reviews, 2016, 99: 28-51.
[6]
Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol in Cancer Res & Treatment, 2005, 4(4): 363-374.
[7]
Gong RD, Chen GM. Preparation and application of functionalized nano drug carriers. J Saudi Pharmaceutical Soc, 2016, 24(3): 254-257.
[8]
Wu LN, Wen XF, Wang XC, et al. Local intratracheal delivery of perfluorocarbon nanoparticles to lung cancer demonstrated with magnetic resonance multimodal imaging. Theranostics, 2018, 8(2): 563-574.
[9]
Li GZ, Lei QF, Wang F, et al. Fluorinated polymer mediated transmucosal peptide delivery for intravesical instillation therapy of bladder cancer. Small, 2019, 15(25): 1900936.
[10]
Kaneda MM, Caruthers SD, Lanza GM, et al. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Annals of Biomedical Engineering, 2009, 37(10): 1922-1933.
[11]
Shimizu M, Kobayashi T, Morimoto H, et al. Tumor imaging with anti-CEA antibody labeled 19F emulsion. Magn Reson in Med, 1987, 5(3): 290-295.
[12]
Mason RP, Antich PP, Babcock EE, et al. Perfluorocarbon imaging in vivo: A 19F MRI study in tumor-bearing mice. Magne Reson Imaging, 1989, 7(5): 475-485.
[13]
Bo SW, Yuan YP, Chen YP, et al. In vivo drug tracking with 19F MRI at therapeutic dose. Chemical Communications, 2018, 54(31): 3875-3878.
[14]
Shin SH, Park E, Min CK, et al. Tracking perfluorocarbon nanoemulsion delivery by 19F MRI for precise high intensity focused ultrasound tumor ablation. Theranostics, 2017, 7(3): 562-572.
[15]
Soman NR, Baldwin SL, Hu G, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest, 2009, 119(9): 2830-2842.
[16]
Wang Y, Sui G, Teng D, et al. Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma. Biomater Sci, 2018, 7(1): 196-210.
[17]
Pan H, Myerson JW, Hu LZ, et al. Programmable nanoparticle functionalization for in vivo targeting. The FASEB J, 2013, 27(1): 255-264.
[18]
Pan DJ, Kim B, Hu G, et al. A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy. Nanomedicine, 2015, 10(2): 241-251.
[19]
Vuquang H, Vinding MS, Nielsen T, et al. Theranostic tumor targeted nanoparticles combining drug delivery with dual near infrared and 19F magnetic resonance imaging modalities. Nanomedicine, 2016, 12(7): 1873-1884.
[20]
Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta implications for plaque vulnerability. Circulation, 2004, 110(14): 2032-2038.
[21]
Moreno PR, Purushothaman K, Sirol M, et al. Neovascularization in human atherosclerosis. Circulation, 2006, 113(18): 2245-2252.
[22]
Winter PM, Neubauer AM, Caruthers SD, et al. Endothelial ανβ3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol, 2006, 26(9): 2103-2109.
[23]
Winter PM, Caruthers SD, Zhang HY, et al. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. Jacc-cardiovascular Imaging, 2008, 1(5): 624-634.
[24]
Marsh JN, Senpan A, Hu G, et al. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine, 2007, 2(4): 533-543.
[25]
Cho MH, Shin SH, Park SH, et al. Targeted, stimuli-responsive, and theranostic 19F magnetic resonance imaging probes. Bioconjugate Chemistry, 2019, 30(10): 2502-25018.
[26]
Ma M, Xu H, Chen H, et al. A drug-perfluorocarbon nanoemulsion with an ultrathin silica coating for the synergistic effect of chemotherapy and ablation by high-intensity focused ultrasound. Adv Mater, 2014, 26(43): 7378-7385.
[27]
Wang ML, Yang QM, Li M, et al. Multifunctional nanoparticles for multimodal imaging-guided low-intensity focused ultrasound/immunosynergistic retinoblastoma therapy. ACS Applied Materials & Interfaces, 2020, 12(5): 5642-5657.
[28]
Liu J, Xu F, Huang J, et al. Low-intensity focused ultrasound (LIFU)-activated nanodroplets as a theranostic agent for noninvasive cancer molecular imaging and drug delivery. Biomater Sci, 2018, 6(11): 2838-2849.
[29]
Zhang L, Yin TH, Li B, et al. Size-modulable nanoprobe for high-performance ultrasound imaging and drug delivery against cancer. ACS Nano, 2018, 12(4): 3449-3460.
[30]
Wang X, Chen HR, Zhang K, et al. An intelligent nanotheranostic agent for targeting, redox-responsive ultrasound imaging, and imaging-guided high-intensity focused ultrasound synergistic therapy. Small, 2014, 10(7): 1403-1411.

PREV Research progress of functional magnetic resonance imaging in chronic kidney disease
NEXT Advances in clinical research of radiomics in bone tumors
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn